Stay updated on Pembrolizumab Plus Entinostat in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Plus Entinostat in Melanoma Clinical Trial page.
Latest updates to the Pembrolizumab Plus Entinostat in Melanoma Clinical Trial page
- Check7 days agoChange DetectedRemoved related topics entries for Melanoma and MedlinePlus Genetics from the page. No new core information was added.SummaryDifference0.2%
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedRevision history updated from v3.2.0 to v3.3.2, affecting only metadata and not the study details. No changes to eligibility, endpoints, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check28 days agoChange DetectedThe government funding/operating status notice was removed from the page, while the core study information remains unchanged.SummaryDifference0.4%
- Check36 days agoChange DetectedAdded Melanoma and related topic links (MedlinePlus Genetics) to the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%
- Check43 days agoChange DetectedNo substantive changes detected in the study details; core information such as purpose, eligibility criteria, endpoints, and treatments appears unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%
- Check50 days agoChange DetectedRemoved Melanoma and the related topic MedlinePlus Genetics from the page's Related Topics. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%
Stay in the know with updates to Pembrolizumab Plus Entinostat in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Plus Entinostat in Melanoma Clinical Trial page.